YouTube took down a video Friday posted by the bio-tech firm Aytu BioSience explaining a new UV light treatment for coronavirus patients. Aytu BioScience announced Tuesday the firm is working with Cedars-Sinai and the FDA to determine the efficacy of the treatment.

The video is now labeled, “This video has been removed for violating YouTube’s Terms of Service”.

Original video with now dead link:

TRENDING: Unhinged Quebec Woman Pascale Ferrier Identified as Suspect in Case of Ricin Letter Sent to Trump White House

https://youtu.be/RZHQbKe9TtI

Copy posted and live for now:

Aytu BioScience promoted the video on Twitter Friday morning, “Many are now talking about UV light being used as a treatment for COVID-19. We are proud to have teamed up with @MarkPimentelMD and his team at @CedarsSinai. They developed Healight. Peer-reviewed data will be published in days, but here’s how it works:”

Many are now talking about UV light being used as a treatment for COVID-19. We are proud to have teamed up with @MarkPimentelMD and his team at @CedarsSinai. They developed Healight. Peer-reviewed data will be published in days, but here's how it works: https://t.co/9E6dyOkwhI — Aytu_BioScience (@BioscienceAytu) April 24, 2020

Aytu BioScience said this evening on Twitter that YouTube has not told them why the video was taken down, “That’s correct. We do not have any idea why. Our team has asked for clarification.”

That's correct. We do not have any idea why. Our team has asked for clarification. — Aytu_BioScience (@BioscienceAytu) April 25, 2020

With no explanation from YouTube forthcoming, Aytu BioScience posted the video to Vimeo Friday night:

There is incredible interest in our UV light technology developed by @MarkPimentelMD and his team at @CedarsSinai For reasons still unclear, YouTube disabled the link. If you're interested in how our technology is designed to work, here is a new link. https://t.co/n1dkFGRlLH — Aytu_BioScience (@BioscienceAytu) April 25, 2020

An excerpt from the video can also be seen at RushLimbaugh.com

Excerpt from the Aytu BioScience press release this week: